Fundraising Fox
Clearflow
Irvine, US · Founded 2007 · Delaware corporation · 25 employees on LinkedIn · 3 known investors
Find your way into Clearflow
Sign up to see every warm intro you have to Clearflow
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Clearflow team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ClearFlow develops PleuraFlow Active Clearance Technology, a device that maintains chest drain patency after cardiac surgery to reduce Retained Blood Syndrome complications, along with products for sternal fixation and reconstruction following sternotomy. The products are used in ICU and surgical settings for post-cardiac-surgery patient care.
Founders & leadership
Clearflow was founded in 2007 by Edward M. Boyle.
EM
Edward M. BoyleFounderEdward Boyle is a cardiovascular and thoracic surgeon who founded ClearFlow Medical, a venture-backed medical device company focused on cardiac surgery solutions, and previously founded Elixis, a healthcare IT company acquired by General Electric. He completed medical school at the University of Minnesota and cardiothoracic surgery training at the University of Washington.
PM
Paul MolloyExecutivePaul Molloy is a CEO and board director with experience across public and private medical device companies, including leadership roles in global operations, R&D, and commercial development. He has led multiple companies through growth phases and exits, including one IPO.
HB
Hannah BeathardExecutiveHannah Beathard is Executive Officer at ClearFlow, which develops PleuraFlow Active Clearance Technology, a device designed to maintain chest drain patency after cardiac surgery and reduce complications including Retained Blood Syndrome and postoperative atrial fibrillation.
Board
AS
NS
AD
Andrew D. FirlikBoard director
CM
Christopher MartinBoard director
EM
Edward M. Boyle, Jr.Board director
Investors · 3
Aphelion Capitallisted by Aphelion Capital
How we know: a partner's Signal profile · Not right? Tell us
California Technology Ventureslisted by California Technology VenturesPasadena · $250K – $2M
How we know: California Technology Ventures's portfolio page · Not right? Tell us
Oregon Venture Fundlisted by Oregon Venture FundPortland · $500K – $5M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$49.4M disclosed across 9 rounds · 2011–2025
▶$2.1MraisedAug 2025 · 2 investors · Other Health CareRule 506(b)
▶$2.1MraisedAug 2025 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul MolloyExecutive Officer, Director
- Alexander SuhDirector
- Edward M. BoyleDirector
- Christopher MartinDirector
- Hannah BeathardExecutive Officer
- Ned ScheetzDirector
- Offering amount
- $4M
- Amount sold
- $2.1M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedJun 2024 · 2 investors · Other Health CareRule 506(b)
▶$2.3MraisedJun 2024 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ned ScheetzDirector
- Hannah BeathardExecutive Officer
- Paul MolloyExecutive Officer, Director
- Edward M. BoyleDirector
- Alexander SuhDirector
- Christopher MartinDirector
- Offering amount
- $3M
- Amount sold
- $2.3M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedAug 2020 · 5 investors · Other Health CareRule 506(b)
▶$7.5MraisedAug 2020 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Christopher MartinDirector
- Paul MolloyExecutive Officer, Director
- Alexander SuhDirector
- Edward M. BoyleDirector
- Ned ScheetzDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.6MraisedMay 2019 · 8 investors · Other Health CareRule 506(b)
▶$7.6MraisedMay 2019 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Alexander SuhDirector
- Paul MolloyExecutive Officer, Director
- Edward M. BoyleDirector
- Ned ScheetzDirector
- Offering amount
- $12M
- Amount sold
- $7.6M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.5MraisedAug 2018 · 6 investors · Other Health CareRule 506(b)
▶$12.5MraisedAug 2018 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Paul MolloyExecutive Officer, Director
- Offering amount
- $12.5M
- Amount sold
- $12.5M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedAug 2015 · 2 investors · Other Health CareRule 506(b)
▶$5.5MraisedAug 2015 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward M. Boyle, Jr.Director
- Andrew D. FirlikDirector
- Ned ScheetzDirector
- Alexander suhDirector
- Paul MolloyExecutive Officer, Director
- Offering amount
- $8.5M
- Amount sold
- $5.5M
- Minimum investment
- $2.8M
- First sale
- Jul 2015
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedNov 2014 · 3 investors · Other Health CareRule 506(b)
▶$2.8MraisedNov 2014 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ned ScheetzDirector
- Andrew D FirlikDirector
- Edward M Boyle, Jr.Director
- Paul MolloyExecutive Officer, Director
- Alexander SuhDirector
- Offering amount
- $5M
- Amount sold
- $2.8M
- Minimum investment
- $240K
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedFeb 2014 · 5 investors · Other Health CareRule 506(b)
▶$4.2MraisedFeb 2014 · 5 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Edward M. Boyle, Jr.Director
- Alexander SuhDirector
- Ned ScheetzDirector
- Andrew FirlikDirector
- Molloy PaulExecutive Officer, Director
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Minimum investment
- $150K
- First sale
- Nov 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Clearflow went on to found or lead other companies.
Related companies · 2
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
Companies working in the same space as Clearflow.
In the news
Frequently asked questions
- What does Clearflow do?
- ClearFlow develops PleuraFlow Active Clearance Technology, a device that maintains chest drain patency after cardiac surgery to reduce Retained Blood Syndrome complications, along with products for sternal fixation and reconstruction following sternotomy. The products are used in ICU and surgical settings for post-cardiac-surgery patient care.
- Who founded Clearflow?
- Clearflow was founded by Edward M. Boyle in 2007.
- Who are Clearflow's investors?
- Clearflow's investors include Aphelion Capital, California Technology Ventures, Oregon Venture Fund.
- How much funding has Clearflow raised?
- Clearflow has disclosed $49.4M raised across 9 rounds.
- Where is Clearflow headquartered?
- Clearflow is headquartered in Irvine, US.